DaVita Stock - Weekly review and sector backdrop without fresh headlines
19.06.2026 - 22:24:16 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 22:21 CET. Details in the imprint.
DaVita (US23804L1035) ends this week without a new market-moving announcement from management or regulators. With no fresh filings or major wire headlines on Friday, the focus turns to how the stock has traded over the week and how the business compares within the US healthcare provider sector.
All news and data on DaVita stock
Key figures, background and previous coverage on DaVita stock can be found bundled in the ad-hoc-news topic area and on the company's investor relations pages.
What this quiet week shows
Across the week, DaVita shares moved in a relatively narrow band, reflecting a lack of stock-specific catalysts and a broader healthcare tape that has traded without a clear trend. Price data from brokerage portals show an intraday range on Friday between about $206.90 and $213.10 for the stock. Robinhood quote overview
At Friday's latest quote of around $207.90, DaVita's market capitalization stands near $13.3 billion, implying a price/earnings multiple just under 20 based on recent earnings. Yahoo Finance key data for DVA Against that backdrop, the stock has slightly lagged the technology-heavy Nasdaq this week but has broadly tracked the Standard & Poor's 500 index.
How DaVita stacks up against peers
On a sector basis, DaVita sits within the US health care providers and services group, alongside diversified giants such as UnitedHealth Group and dialysis competitor Fresenius Medical Care's ADR. Over recent months, dialysis-focused names have faced ongoing reimbursement and regulatory discussion in Washington, a recurring theme for the space. Financial Times reporting on US healthcare policy debates
Compared with some managed-care peers, DaVita trades on a mid-teens to high-teens earnings multiple, reflecting its narrower dialysis focus and exposure to reimbursement risk. All told, the stock's valuation appears more in line with specialized healthcare service providers than with the highest-rated US insurers.
How the company makes its money
DaVita generates the bulk of its revenue by operating outpatient dialysis centers and related kidney care services for patients with chronic kidney failure. The company runs thousands of facilities worldwide, with a heavy concentration in the United States, and is reimbursed primarily through government programs and private insurers.
Where the stock trades today
The shares of DaVita (US23804L1035) trade on the New York Stock Exchange at approximately $207.91 as of 06/19/2026, 17:30 CET.
Key facts on DaVita stock
- Company: DaVita Inc.
- ISIN: US23804L1035
- Ticker: DVA
- Venue: NYSE
- Price (as of 06/19/2026, 17:30 CET): 207.91 USD
- Market cap: 13.35 billion USD (as of 06/19/2026)
- Sector / Industry: Health Care - Health Care Providers & Services
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
